由BRAFV600E驱动的瘤发生需要克服其反抑制RAC1和迁移的二次突变

相关实验视频

Updated: May 26, 2025

06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Sunyana Gadal¹, Jacob A Boyer², Simon F Roy^3,4

¹Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer research

|February 24, 2025

概括

BRAF V600E突变促进细胞增殖,但抑制迁移. 通过挽救这种迁移缺陷,二次突变是黑色素瘤发展所需的,突出了潜在的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

BRAF V600E突变在黑色素瘤中很常见,通过ERK信号传递驱动扩散.
然而,单独BRAF V600E对黑色素瘤的发展是不够的,因为它也发生在良性瘤中.

研究的目的:

调查为什么BRAF V600E突变并不总是导致黑色素瘤.
为了确定黑色素瘤进展的机制,尽管BRAF V600E诱导的信号.

主要方法:

利用基因工程小鼠模型和人类良性瘤/黑色素瘤样本.
分析了BRAF V600E对细胞迁移和信号通路 (ERK,RAC1) 的影响.
研究了二次突变 (RAC1,PTEN) 在恢复细胞移动性的作用.

主要成果:

BRAF V600E通过反抑制RAC1活动来抑制中酶体迁移.
抑制ERK通路或二次突变 (突变RAC1,PTEN失活) 恢复RAC1活动和细胞迁移.
这些救援突变存在于26%的BRAF V600E突变黑色素瘤中.

结论:

由BRAF V600E驱动的ERK信号放松了扩散的调节,但通过抑制RAC1依赖的迁移来阻碍恶性转变.
拯救这种迁移缺陷的二次遗传病变对于黑色素瘤瘤发生是必不可少的.
瘤反机制可能会塑造瘤的遗传格局,选择潜在的治疗标的突变.

相关概念视频

02:38

The Ras Gene

6.1K

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

6.1K

02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.4K

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

11.4K

03:03

mTOR Signaling and Cancer Progression

3.7K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

3.7K

01:35

Cancer Cell Migration through Invadopodia

2.3K

Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...

2.3K

01:24

Small GTPases - Ras and Rho

3.9K

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

3.9K

02:07

Tumor Progression

6.2K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...